Quartz says four in ten patients stop GLP-1 drugs, and looks at a newer injection built around the reason they drop off.
Recap by typeshit. Post by Quartz on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Moises Rivera Jr. filed his complaint on October 9 in the federal GLP-1 vision loss MDL, joining hundreds of similar failure-to-warn claims now in front of Judge Karen Marston.
The piece recaps Phase 3 weight loss of up to 28.3% and notes TRIUMPH-3 didn't show fewer major heart events. Lilly aims to file in early 2027.
Loading…